REPLAGAL

Phase 3

TAKEDA PHARMACEUTICAL CO LTD (TAK)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

2 competitors in Fabry Disease

IDRS.SWLucerastat

Phase 3

View Full Landscape

Drug Information

Target Indication

Fabry Disease

Clinical Trial

NCT04974749

Last updated: 2/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/3/2001

Replagal

Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

TAK

TAKEDA PHARMACEUTICAL CO LTD

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3

Hypertension

HYQVIAPhase 3

Primary Immunodeficiency Diseases (PID)

Alogliptin and pioglitazonePhase 3

Type 2 Diabetes Mellitus

IGSC 20% infusionPhase 3

Primary Immunodeficiency Disease

Lapaquistat acetate and atorvastatinPhase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts